-
Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page
Mirati - oncology?
- Thread starter anonymous
- Start date
-
- Tags
- None
The fair market price shouldn't be any more than that, probably less.
I guess the markets are not falling for their latest biomarker horse shit story, just like the last one! Swill Merchants.
Meat is bad news. Cancel Christmas and drink egg knock now!
Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs
Do you really think it’ll make a difference?
Fierce Biotech: Lilly challenges Amgen, Mirati with early KRAS data
https://www.fiercebiotech.com/biote...data-heading-field-much-less-crowded-it-seems
KRAS inhibitors arrived on the market in May 2021 and December 2022 to much fanfare—but, if you ask Eli Lilly’s Loxo unit, the therapies have left much to be desired.
Amgen’s Lumakras and Mirati Therapeutics’ Krazati are “modestly effective” and have not led to the “dramatic advance for patients” that was initially thought possible when the once undruggable target was finally hacked, according to Jake Van Naarden, executive vice president at Lilly and CEO of Loxo@Lilly. Specifically, to make a real dent in the market, he said, KRAS inhibitors need to combine with standard-of-care PD-1 treatment—which in Loxo's opinion has not been smooth sailing for the first-to-market winners.
https://www.fiercebiotech.com/biote...data-heading-field-much-less-crowded-it-seems
KRAS inhibitors arrived on the market in May 2021 and December 2022 to much fanfare—but, if you ask Eli Lilly’s Loxo unit, the therapies have left much to be desired.
Amgen’s Lumakras and Mirati Therapeutics’ Krazati are “modestly effective” and have not led to the “dramatic advance for patients” that was initially thought possible when the once undruggable target was finally hacked, according to Jake Van Naarden, executive vice president at Lilly and CEO of Loxo@Lilly. Specifically, to make a real dent in the market, he said, KRAS inhibitors need to combine with standard-of-care PD-1 treatment—which in Loxo's opinion has not been smooth sailing for the first-to-market winners.